loading
Kiora Pharmaceuticals Inc stock is traded at $2.55, with a volume of 41,172. It is down -1.54% in the last 24 hours and up +2.82% over the past month. Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$2.59
Open:
$2.53
24h Volume:
41,172
Relative Volume:
1.43
Market Cap:
$11.28M
Revenue:
$20,000
Net Income/Loss:
$-11.06M
P/E Ratio:
-0.8963
EPS:
-2.8449
Net Cash Flow:
$-10.53M
1W Performance:
-3.41%
1M Performance:
+2.82%
6M Performance:
+22.60%
1Y Performance:
+0.79%
1-Day Range:
Value
$2.48
$2.585
1-Week Range:
Value
$2.48
$2.65
52-Week Range:
Value
$1.7645
$3.01

Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile

Name
Name
Kiora Pharmaceuticals Inc
Name
Phone
858-224-9600
Name
Address
169 SAXONY RD., ENCINITAS
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
2026-08-14
Name
Latest SEC Filings
Name
KPRX's Discussions on Twitter

Compare KPRX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
KPRX icon
KPRX
Kiora Pharmaceuticals Inc
2.55 11.68M 20,000 -11.06M -10.53M -2.8449
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
505.75 133.25B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
803.48 82.16B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
851.29 54.80B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
203.71 43.99B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
347.48 40.62B 5.76B 514.49M 1.10B 4.4813

Kiora Pharmaceuticals Inc Stock (KPRX) Latest News

pulisher
Aug 14, 2026

Perceptive Advisors LLC Acquires New Position in Kiora Pharmaceuticals Inc (KPRX) - GuruFocus

Aug 14, 2026
pulisher
Aug 14, 2026

ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing - Stock Titan

Aug 14, 2026
pulisher
Aug 10, 2026

Kiora Pharmaceuticals (KPRX) reports 9.99% stake held by Perceptive group - Stock Titan

Aug 10, 2026
pulisher
Aug 08, 2026

Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com - Investing.com Nigeria

Aug 08, 2026
pulisher
Aug 08, 2026

Kiora Pharmaceuticals advances retinal disease trials, secures $24M funding, expects data in 2027 - Pluang

Aug 08, 2026
pulisher
Aug 07, 2026

Kiora Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2026
pulisher
Aug 07, 2026

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile

Aug 07, 2026
pulisher
Aug 07, 2026

Kiora Starts Enrollment in 100-Microgram Retinitis Pigmentosa Cohort - Stock Titan

Aug 07, 2026
pulisher
Aug 05, 2026

Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 ResistanceGap and Reverse - dars.gov.et

Aug 05, 2026
pulisher
Jul 27, 2026

Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Kiora Pharmaceuticals Market Sentiment - Benzinga España

Jul 27, 2026
pulisher
Jul 27, 2026

Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

KPRX|Kiora Pharmaceuticals Inc|Price:2.530|Chg%:-0.020 - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

TradingKey - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

Kiora Pharmaceuticals Q1 2026 Earnings: EPS Beat as Pre‑Revenue Biotech Narrows Loss ExpectationsPerformance Review - dars.gov.et

Jul 26, 2026
pulisher
Jul 25, 2026

Kiora Pharmaceuticals (KPRX) Edges Higher as Shares Test Key ResistanceKAMA Signal - dars.gov.et

Jul 25, 2026
pulisher
Jul 25, 2026

Kiora Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:KPRX - TradingView

Jul 25, 2026
pulisher
Jul 24, 2026

Kiora Pharmaceuticals Inc (KPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 21, 2026

Kiora Pharmaceuticals (KPRX) Slips 2.7% as Biotech Sector Faces Renewed PressureVolume Climax - dars.gov.et

Jul 21, 2026
pulisher
Jul 18, 2026

Price to sales forward of Kiora Pharmaceuticals, Inc. – FWB:7EY - TradingView

Jul 18, 2026
pulisher
Jul 17, 2026

Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – FWB:7EY - TradingView

Jul 17, 2026
pulisher
Jul 10, 2026

Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – LS:A40EG5 - TradingView

Jul 10, 2026
pulisher
Jul 09, 2026

Kiora Pharmaceuticals Inc. (KPRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Jul 09, 2026
pulisher
Jul 07, 2026

Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – GETTEX:7EY - TradingView

Jul 07, 2026
pulisher
Jul 05, 2026

Price to earnings forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView

Jul 05, 2026
pulisher
Jul 04, 2026

Price to book forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView

Jul 04, 2026
pulisher
Jul 04, 2026

Enterprise value to EBITDA forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView

Jul 04, 2026
pulisher
Jul 04, 2026

KPRXKiora Pharmaceuticals Inc Latest SEC Filings - Finviz

Jul 04, 2026
pulisher
Jul 02, 2026

Form 4 Kiora Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com India

Jul 02, 2026
pulisher
Jul 02, 2026

Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations - Stock Titan

Jul 02, 2026
pulisher
Jul 02, 2026

[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan

Jul 02, 2026
pulisher
Jul 02, 2026

Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector WatchesRelative Volume - dars.gov.et

Jul 02, 2026
pulisher
Jul 02, 2026

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium - TMX Newsfile

Jul 02, 2026
pulisher
Jul 01, 2026

Kiora Pharmaceuticals Inc Warrant 2022-27.09.27 on Kiora Pharma A Financial Disclosures & SEC Filings - TradingView

Jul 01, 2026
pulisher
Jun 28, 2026

Kiora Pharmaceuticals (KPRX) Slides Marginally as Biotech Sector Remains CautiousMonthly Profile - po-news-eg.net

Jun 28, 2026
pulisher
Jun 26, 2026

Kiora Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:KPRX) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

KPRX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

7EY Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 24, 2026

Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits

Jun 24, 2026
pulisher
Jun 24, 2026

Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence - TradingKey

Jun 24, 2026
pulisher
Jun 22, 2026

Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 22, 2026
pulisher
Jun 21, 2026

Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX) - The Globe and Mail

Jun 21, 2026
pulisher
Jun 20, 2026

Kiora Pharmaceuticals (KPRX) Slips Slightly as Stock Hovers Near Key Support ZoneDouble Top - dars.gov.et

Jun 20, 2026
pulisher
Jun 19, 2026

KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 19, 2026
pulisher
Jun 18, 2026

Kiora Pharmaceuticals (KPRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

Jun 18, 2026
pulisher
Jun 18, 2026

Kiora Pharmaceuticals’ KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 – Minichart - Minichart

Jun 18, 2026
pulisher
Jun 18, 2026

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model - TMX Newsfile

Jun 18, 2026
pulisher
Jun 18, 2026

Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data - Stock Titan

Jun 18, 2026
pulisher
Jun 18, 2026

Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 18, 2026

Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$63.32
price down icon 0.52%
$58.60
price up icon 0.07%
$36.20
price down icon 0.22%
$123.74
price down icon 2.05%
$228.65
price up icon 0.67%
ONC ONC
$347.48
price down icon 2.40%
Cap:     |  Volume (24h):